

New Dinuclear Ru₂(CO)₄ Sawhorse-Type Complexes Containing Bridging Carboxylato Ligands

Mathieu Auzias,^[a] Johan Mattsson,^[a] Bruno Therrien,^[a] and Georg Süss-Fink^{*[a]}

Abstract. The thermal reaction of Ru₃(CO)₁₂ with ethacrynic acid, 4-[bis(2-chlorethyl)amino]benzenebutanoic acid (chlorambucil), or 4-phenylbutyric acid in refluxing solvents, followed by addition of two-electron donor ligands (L), gives the diruthenium complexes Ru₂(CO)₄(O₂CR)₂L₂ (**1**: R = CH₂O-C₆H₂Cl₂-COC(CH₂)C₂H₅, L = C₅H₅N; **2**: R = CH₂O-C₆H₂Cl₂-COC(CH₂)C₂H₅, L = PPh₃; **3**: R = C₃H₆-C₆H₄-N(C₂H₄-Cl)₂, L = C₅H₅N; **4**: R =

C₃H₆-C₆H₄-N(C₂H₄-Cl)₂, L = PPh₃; **5**: R = C₃H₆-C₆H₅, L = C₅H₅N; **6**: R = C₃H₆-C₆H₅, L = PPh₃). The single-crystal structure analyses of **2**, **3**, **5** and **6** reveal a dinuclear Ru₂(CO)₄ sawhorse structure, the diruthenium backbone being bridged by the carboxylato ligands, while the two L ligands occupy the axial positions of the diruthenium unit.

Keywords: Carbonyl ligands; Carboxylato bridges; Dinuclear complexes; Ruthenium

Introduction

Sawhorse-type diruthenium complexes are well-known since 1969, when J. Lewis and co-workers reported their formation by refluxing Ru₃(CO)₁₂ in the corresponding carboxylic acid and the depolymerisation of the materials obtained in coordinating solvents to give dinuclear complexes of the type Ru₂(CO)₄(O₂CR)₂L₂ (R = H, CH₃, C₂H₅, C₉H₁₉; L = C₅H₅N, AsPh₃, PPh₃), L being a two-electron donor ligand [1]. Later, by a single-crystal X-ray structure analysis of Ru₂(CO)₄(O₂CR)₂L₂ (R = C₄H₉; L = PBu^t₃), these complexes have been shown to have a Ru₂(CO)₄ backbone in a sawhorse-type arrangement with two μ₂-η²-carboxylato bridges and two axial ligands [2]. Since their discovery, a considerable number of such sawhorse-type diruthenium complexes with carboxylato bridges have been synthesized [3], and used in various fields as well as catalysis [4, 5, 6] or to synthesize metallo-mesomorphic materials [7].

Herein, we report the synthesis and characterization of six new Ru₂(CO)₄ sawhorse-type complexes containing carboxylato ligands, some of which with biologically active substituents. The single-crystal structure analysis of four representative complexes is presented as well.

Experimental Section

General Remarks

All manipulations were carried out by routine under nitrogen atmosphere. Organic solvents were degassed and saturated with ni-

trogen prior to use. All reagents were purchased either from Aldrich or Fluka and used as received. Dodecacarbonyltriruthenium was prepared according to published method [8]. The ¹H, ¹³C{¹H} and ³¹P{¹H} NMR spectra were recorded on a Bruker AMX 400 spectrometer using the residual protonated solvent as internal standard. Infrared spectra were recorded on a Perkin-Elmer FT-IR 1720X spectrometer (4000-400 cm⁻¹). Electro-spray mass spectra were obtained in positive-ion mode with an LCQ Finnigan mass spectrometer.

Synthesis of 1–6

A solution of Ru₃(CO)₁₂ (200 mg, 0.32 mmol) and the corresponding acid (285 mg, 0.94 mmol for ethacrynic acid **1–2**; 288 mg, 0.94 mmol for chlorambucil **3–4**; 154 mg, 0.94 mmol for 4-phenyl-1-butyric acid **5–6**) in dry tetrahydrofuran (30 mL) was heated to 120 °C in a pressure Schlenk tube for 18 h. Then the solvent was evaporated to give a brown residue which was dissolved in tetrahydrofuran and the appropriate ligand L (0.94 mmol) (**1**, **3**, **5**, L = C₅H₅N; **2**, **4**, **6**, L = PPh₃) was added. The solution was stirred at room temperature for two hours, then the solution was evaporated and the product isolated from the residue by crystallization from a tetrahydrofuran/hexane or dichloromethane/hexane mixture. The products were purified by column chromatography on silica gel using dichloromethane as eluent. Complexes **1–6** were obtained as yellow crystalline powders which are stable up to 200 °C.

Ru₂(CO)₄{O₂CCH₂O-C₆H₂Cl₂-COC(CH₂)C₂H₅}₂(C₅H₅N)₂ (1**).
Yield: 68 %, 344 mg, 0.32 mmol.**

¹H NMR (400 MHz, CDCl₃): δ = 8.34 (m, 4H, CH_{pyr}), 7.81 (t, 2H, CH_{pyr}, ³J = 7.6 Hz), 7.32 (m, 4H, CH_{pyr}), 7.10 (d, 2H, CH_{aro}, ³J = 8.6 Hz), 7.04 (d, 2H, CH_{aro}, ³J = 8.6 Hz), 5.90 (s, 2H, CH₂=C), 5.48 (s, 2H, CH₂=C), 4.72 (s, 4H, CH₂COO), 2.46 (q, 4H, CH₂CH₃, ³J = 7.4 Hz), 1.15 (t, 6H, CH₃, ³J = 7.4 Hz). **¹³C{¹H} NMR** (100 MHz, CDCl₃): δ = 206.44 (CO), 195.70 (2C, C=O), 185.78 (COO), 157.17, 156.88 (C-Cl), 151.06 (C-O), 150.22 (C₅H₅N), 137.53 (C₅H₅N), 129.24 (CH₂), 125.34 (C₅H₅N), 111.49 (CH₃), 68.60 (CH₂), 46.54 (CH), 26.61 (CH₂). **IR** (CaF₂, CH₂Cl₂): ν_(CO) 2030 vs, 1978 m, 1947 vs, ν_(OCO) 1613 m, 1585 m cm⁻¹. **ESI-MS**: m/z = 941.79 [M-C₅H₅N-2CO+H]⁺.

* Prof. G. Süss-Fink
Fax: +41-3271-82511
E-Mail: georg.suess-fink@unine.ch
[a] Institut de Chimie, Université de Neuchâtel
Avenue de Bellevaux 51, CP 158, 2009 Neuchâtel, Switzerland

Ru₂(CO)₄{O₂CCH₂O-C₆H₄Cl₂-COC(CH₂)₂C₂H₅}₂(PPh₃)₂ (2).

Yield: 39 %, 260 mg, 0.180 mmol.

¹H NMR (400 MHz, (CD₃)₂CO): δ = 7.61-7.30 (m, 30H, CH_{ar}), 7.07 (d, 2H, CH_{ar}, ³J = 8.6 Hz), 7.10 (d, 2H, CH_{ar}, ³J = 8.6 Hz), 5.95 (s, 2H, CH₂=C), 5.38 (s, 2H, CH₂=C), 4.45 (s, 2H, CH₂COO), 2.43 (q, 4H, CH₂CH₃, ³J = 7.4 Hz), 1.10 (t, 6H, CH₃, ³J = 7.4 Hz). ¹³C{¹H} NMR (100 MHz, (CD₃)₂CO): δ = 205.13 (CO), 195.70 (C=O), 183.90 (COO), 157.19, 156.79 (C-Cl), 151.06 (C-O), 144.80, 139.20, 134.71, 134.50, 134.45, 134.39, 133.81, 133.65, 133.60, 131.06, 129.43, 129.38, 129.34 (CH_{ar}), 129.24 (CH₂), 123.29, 122.78 (CH_{ar}), 111.49 (CH₃), 68.60 (CH₂), 47.06 (CH), 26.61 (CH₂). ³¹P{¹H} NMR (161 MHz, (CD₃)₂CO): δ = 12.68. IR (CaF₂, CH₂Cl₂): ν_(CO) 2028 vs, 1984 m, 1956 vs, ν_(OCO) 1606 m, 1586 cm⁻¹. ESI-MS: m/z = 1443.02 [M+H]⁺, 1466.99 [M-2CO+Na+(CH₃)₂CO]⁺.

Ru₂(CO)₄{O₂CC₃H₆-C₆H₄-N(C₂H₄-Cl)₂}₂(C₅H₅N)₂ (3).

Yield: 81 %, 412 mg, 0.381 mmol.

¹H NMR (400 MHz, CDCl₃): δ = 8.81-8.83 (m, 4H, C₅H₅N), 7.87-7.92 (m, 2H, C₅H₅N), 7.44-7.48 (m, 4H, C₅H₅N), 6.98 (d, 4H, C₆H₄, ³J = 8.7 Hz), 6.58 (d, 4H, C₆H₄, ³J = 8.7 Hz), 3.63-3.75 (m, 16H, N(CH₂)₂Cl), 2.49 (t, 4H, (CH₂)₂CH₂, ³J = 7.2 Hz), 2.36 (t, 4H, (CH₂)₂CH₂, ³J = 7.2 Hz), 1.81-1.92 (m, 4H, CH₂CH₂CH₂). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ = 206.64 (CO), 187.08 (COO), 152.31 (C₅H₅N), 144.57 (CH_{ar}), 137.83 (C₅H₅N), 131.67 (CH_{ar}), 130.08 (CH), 125.34 (C₅H₅N), 112.44 (CH), 54.01, 40.99, 36.72, 34.39, 28.53 (CH₂). IR (CaF₂, CH₂Cl₂): ν_(CO) 2023 vs, 1971 m, 1939 vs, ν_(OCO) 1582 m, 1568 m cm⁻¹. ESI-MS: m/z = 1082.02 [M+H]⁺, 1002.89 [M-C₅H₅N+H]⁺.

Ru₂(CO)₄{O₂CC₃H₆-C₆H₄-N(C₂H₄-Cl)₂}₂(PPh₃)₂ (4).

Yield: 53 %, 357 mg, 0.247 mmol.

¹H NMR (400 MHz, CDCl₃): δ = 7.61-7.57 (m, 12H, CH_{ar}), 7.45-7.36 (m, 18H, CH_{ar}), 6.85 (d, 4H, C₆H₄, ³J = 8.7 Hz), 6.55 (d, 4H, C₆H₄, ³J = 8.7 Hz), 3.75-3.62 (m, 16H, N(CH₂)₂Cl), 2.22 (t, 4H, (CH₂)₂CH₂, ³J = 7.2 Hz), 2.02 (t, 4H, (CH₂)₂CH₂, ³J = 7.2 Hz), 1.34-1.50 (m, 4H, CH₂CH₂CH₂). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ = 205.85 (CO), 188.67 (COO), 144.45 (CH_{ar}), 134.35, 134.29, 134.23, 133.82, 131.72, 130.07, 128.62, 128.59, 128.54 (CH_{ar}), 133.98, 133.67 (CH_{ar}), 112.46 (CH_{ar}), 54.05, 40.98, 36.86, 34.19, 27.99 (CH₂). ³¹P{¹H} NMR (161 MHz, CDCl₃): δ = 14.79. IR (CaF₂, CH₂Cl₂): ν_(CO) 2022 vs, 1974 m, 1943 vs, ν_(OCO) 1614 m, 1585 m cm⁻¹. ESI-MS: m/z = 1469.17 [M+Na]⁺.

Ru₂(CO)₄(O₂CC₃H₆-C₆H₅)₂(C₅H₅N)₂ (5).

Yield: 67 %, 252 mg, 0.316 mmol.

¹H NMR (400 MHz, CDCl₃): δ = 8.76 (m, 4H, C₅H₅N), 7.82 (m, 2H, C₅H₅N), 7.38 (m, 4H, C₅H₅N), 7.13-7.23 (m, 6H, C₆H₅), 7.03 (dd, 4H, C₆H₅, ⁵J = 1.53 Hz, ³J = 6.63 Hz), 2.53 (t, 4H, OOCCH₂CH₂, ³J = 7.8 Hz), 2.32 (t, 4H, CH₂CH₂C₆H₅, ³J = 7.1 Hz), 1.84 (m, 4H, CH₂CH₂CH₂). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ = 204.15 (CO), 186.50 (COO), 151.87 (C₅H₅N), 142.07 (C₆H₄), 137.32 (C₅H₅N), 128.41 (C₆H₄), 128.23 (C₆H₄), 125.72 (C₆H₄), 124.85 (C₅H₅N), 36.29 (CH₂), 35.15 (CH₂), 27.83 (CH₂). IR (CaF₂, CH₂Cl₂): ν_(CO) 2023 vs, 1971 m, 1938 vs, ν_(OCO) 1600 w, 1569 m cm⁻¹. ESI-MS: m/z = 821.5 [M+Na]⁺, 742.7 [M-2CO+H]⁺.

Ru₂(CO)₄(O₂CC₃H₆-C₆H₅)₂(PPh₃)₂ (6).

Yield: 69 %, 206 mg, 0.177 mmol.

¹H NMR (400 MHz, CDCl₃): δ = 7.53 (m, 12H, PPh₃), 7.33 (m, 18H, PPh₃), 7.17 (m, 6H, C₆H₅), 6.89 (m, 4H, C₆H₅), 2.25 (t, 4H, OOCCH₂CH₂, ³J = 7.7 Hz), 1.96 (t, 4H, CH₂CH₂C₆H₅, ³J = 7.4 Hz), 1.42 (m, 4H, CH₂CH₂CH₂C₆H₅). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ = 205.66 (CO), 188.30 (COO), 142.24 (C_{ar}), 134.12 (C_{ar}), 134.06 (C_{ar}), 134.00 (C_{ar}), 133.69 (C_{ar}), 133.53 (C_{ar}), 133.37 (C_{ar}), 129.86 (C_{ar}), 128.66 (C_{ar}), 128.41 (C_{ar}), 128.37 (C_{ar}), 128.32 (C_{ar}), 125.82 (C_{ar}), 36.76 (CH₂), 35.25 (CH₂), 27.57 (CH₂). ³¹P{¹H} NMR (161 MHz, CDCl₃): δ = 12.72 ppm. IR (CaF₂, CH₂Cl₂): ν_(CO) 2022 vs, 1977 m, 1949 s, ν_(OCO) 1566 s cm⁻¹. ESI-MS: m/z = 1187.6 [M+Na]⁺, 845.1 [M-PPh₃-3CO+Na+CH₃OH]⁺.

Alternative Synthesis of 5 and 6

A suspension of Ru₃(CO)₁₂ (111 mg, 0.174 mmol) and 4-phenyl-1-butylbutyric acid (85 mg, 0.515 mmol) in dry methanol (50 ml) was refluxed (bath temperature 70 °C) under inert atmosphere in a classical Schlenk tube overnight. After filtration of the methanol solu-

tion, a CH₂Cl₂ solution (20 mL) of the appropriate ligand L (0.515 mmol) C₅H₅N (5) or PPh₃ (6) was added. Then the solution was stirred at room temperature for two hours. The volume of the solvent was then reduced and the product was precipitated by addition of hexane. The product was obtained as a yellow powder. Yields: 67 % (5) and 69 % (6).

X-ray Crystallographic Study

Yellow crystals of **2**, **3**, **5** and **6** were mounted at 203 K on a Stoe Image Plate Diffraction system equipped with a φ circle goniometer, using Mo-Kα graphite monochromated radiation (λ = 0.71073 Å) with φ range 0-200°. The structures were solved by direct methods using the program SHELXS-97 [9]. Refinement and all further calculations were carried out using SHELXL-97 [10]. The H-atoms were included in calculated positions and treated as riding atoms using the SHELXL default parameters. The non-H atoms were refined anisotropically, using weighted full-matrix least-square on F².

Crystal data for 2; C₆₆H₅₂Cl₄O₁₂P₂Ru₂, triclinic space group P $\bar{1}$ (No. 2), cell parameters *a* = 10.1138(9), *b* = 15.4929(13), *c* = 21.1252(17) Å, α = 91.972(10), β = 96.308(10), γ = 108.582(9)°, *V* = 3110.1(5) Å³, *Z* = 2, *D_c* = 1.541 g cm⁻³, *F*(000) 1460, 11372 reflections measured, 8944 unique (*R_{int}* = 0.0308) which were used in all calculations. *R₁* = 0.0524 (*I* > 2σ(*I*)) and *wR₂* = 0.1594, GOF = 1.081; max./min. residual density 2.787/−1.592 eÅ⁻³.

Crystal data for 3; C₄₂H₄₆Cl₄N₄O₈Ru₂, triclinic space group P $\bar{1}$ (No. 2), cell parameters *a* = 10.2849(12), *b* = 11.1549(13), *c* = 20.220(3) Å, α = 95.111(10), β = 94.363(10), γ = 104.394(9)°, *V* = 2226.4(5) Å³, *Z* = 2, *D_c* = 1.609 g cm⁻³, *F*(000) 1092, 7868 reflections measured, 5227 unique (*R_{int}* = 0.0906) which were used in all calculations. *R₁* = 0.0496 (*I* > 2σ(*I*)) and *wR₂* = 0.1227, GOF = 0.918; max./min. residual density 0.554/−0.942 eÅ⁻³.


Crystal data for 5; C₃₄H₃₂N₂O₈Ru₂, triclinic space group P $\bar{1}$ (No. 2), cell parameters *a* = 9.614(4), *b* = 10.713(4), *c* = 17.766(9) Å, α = 73.17(5), β = 88.74(5), γ = 72.71(5)°, *V* = 1668.3(12) Å³, *Z* = 2, *D_c* = 1.590 g cm⁻³, *F*(000) 804, 6070 reflections measured, 4331 unique (*R_{int}* = 0.0642) which were used in all calculations. *R₁* = 0.0403 (*I* > 2σ(*I*)) and *wR₂* = 0.1011, GOF = 0.915; max./min. residual density 0.838/−1.007 eÅ⁻³.

Crystal data for 6; C₆₀H₅₂O₈P₂Ru₂, monoclinic space group P2₁/*n* (No. 14), cell parameters *a* = 15.2072(9), *b* = 39.987(2), *c* = 17.5163(11) Å, β = 90.797(5)°, *V* = 10650.4(11) Å³, *Z* = 8, *D_c* = 1.453 g cm⁻³, *F*(000) 4752, 18938 reflections measured, 8571 unique (*R_{int}* = 0.1735) which were used in all calculations. *R₁* = 0.0650 (*I* > 2σ(*I*)) and *wR₂* = 0.1572, GOF = 0.834; max./min. residual density 0.661/−1.436 eÅ⁻³. Figures 1 to 4 were drawn with ORTEP [11].

CCDC 698270 (2), 698271 (3), 698272 (5) and 698273 (6) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.


Results and Discussion**Synthesis**

In a high pressure Schlenk tube, dodecacarbonyltriruthenium reacts first with the appropriate carboxylic acid in



Scheme 1.

tetrahydrofuran at 120 °C to yield the corresponding thf-intermediates [Ru₂(CO)₄(O₂CR)₂(thf)₂], which react with two-electron donor ligands L such as pyridine or triphenylphosphine to give the complexes Ru₂(CO)₄(O₂CR)₂L₂ **1–6** in good yields according to Equation (1).



Compounds **1–6** are air-stable yellow crystalline powders which have been characterized by IR, NMR and mass spectroscopy. All compounds exhibit in the ν_{CO} region of the infrared spectrum the characteristic pattern of the Ru₂(CO)₄ sawhorse unit: three bands around 2000 cm⁻¹ for the CO terminal ligands and two bands for symmetric and asymmetric vibrations of the carboxylato bridges, around 1500–1600 cm⁻¹ [1].

A convenient method for the synthesis of diruthenium sawhorse-type complexes avoiding pressure Schlenk tube heating was reported by *A. H. White* and co-workers [12]. We therefore tried to find out if refluxing conditions are sufficient for the synthesis of our complexes. Indeed, refluxing Ru₃(CO)₁₂ and the corresponding carboxylic acid in methanol turned out to be adequate. The yields, however, are not higher: In the case of **5** and **6**, the yields are identical to those obtained in the classical high-temperature synthesis.

Crystal Structures

Crystals suitable for X-ray structural analysis were obtained by slow diffusion of hexane in concentrated solutions of **2**, **3**, **5** and **6** in chloroform. The single-crystal structure analyses of **2**, **3**, **5** and **6** exhibit the Ru₂(CO)₄ sawhorse backbone with the two two-electron donor ligands in the axial positions and the carboxylato bridges in the equatorial positions. The molecular structures of **2**, **3**, **5** and **6** are shown in Figures 1, 2, 3 and 4, respectively, and a series of selected geometrical parameters are presented in Table 1.

All Ru–Ru distances are in the range of a ruthenium–ruthenium single bond but they are considerably shorter in the pyridine derivatives **3** and **5** (2.6816(7) and 2.669(1) Å)

than those of the triphenylphosphine analogues **2** and **6** (2.7107(9) to 2.7197(6) Å). This difference in the metal–metal separation can be associated to an increase in electron density between the metal atoms as a result of the lack of back-bonding to the NC₅H₅ ligands.




Figure 1. ORTEP drawing of **2**, at 50% probability level for thermal displacement ellipsoids, with hydrogen atoms being omitted for clarity.





Figure 2. ORTEP drawing of **3**, at 50% probability level for thermal displacement ellipsoids, with hydrogen atoms being omitted for clarity.

Table 1. Selected bond lengths /Å and angles /° for **2**, **3**, **5** and **6**


L =	2 PPh ₃	3 NC ₅ H ₅	5 NC ₅ H ₅	6A PPh ₃	6B PPh ₃
<i>Distances</i>					
Ru–Ru	2.7197(6)	2.6816(7)	2.6689(13)	2.7107(9)	2.7156(9)
Ru–L(1)	2.424(1)	2.223(5)	2.221(4)	2.429(2)	2.427(2)
Ru–L(2)	2.454(1)	2.239(5)	2.228(4)	2.435(2)	2.446(2)
Ru–O _{carboxylato}	2.128(3)	2.113(4)	2.113(3)	2.129(5)	2.120(6)
Ru–O _{carboxylato}	2.143(3)	2.124(3)	2.129(3)	2.164(5)	2.121(6)
Ru–O _{carboxylato}	2.122(3)	2.119(4)	2.113(3)	2.120(6)	2.143(5)
Ru–O _{carboxylato}	2.147(3)	2.136(4)	2.126(3)	2.127(6)	2.144(5)
<i>Angles</i>					
O _{carboxylato}					
O–Ru–O	86.2(1)	85.1(1)	84.9(1)	85.4(2)	84.1(2)
O–Ru–O	85.4(1)	86.2(1)	83.8(1)	82.2(2)	81.7(2)
C _{carbonyl}					
C–Ru–C	89.7(2)	89.2(2)	87.7(2)	88.0(4)	89.2(4)
C–Ru–C	88.3(2)	89.2(2)	90.2(2)	90.1(4)	89.7(4)
<i>Torsion angles</i>					
L–Ru–Ru–L	–18.5(2)	–8.2(5)	–3.0(4)	32.5(5)	–40.1(5)

**Figure 3.** ORTEP drawing of **5**, at 50 % probability level for thermal displacement ellipsoids, with hydrogen atoms omitted for clarity.

The OCO bond angles of the carboxylato bridges [**2**: 126.6(4) and 127.9(4)°, **3**: 125.9(5) and 127.0(5)°, **5**: 124.9(4) and 125.0(4)°, **6A**: 124.2(8) and 125.4(8)°, **6B**: 123.5(8) and 125.1(7)°] differ only slightly from those observed in other Ru₂(CO)₄(O₂CR)₂L₂ complexes [2, 3b, 3d].

The unit cell of complex **6** contains two symmetry-independent molecules, identified **6A** and **6B**, respectively. However, the two molecules are almost identical, the main difference being in the relative position of the phenyl rings of the two coordinated phenylbutyl carboxylato bridging ligands.

Diruthenium sawhorse-type complexes containing porphyrin-derived ligands show interesting anti-cancer properties [13]. Ethacrynic acid and chlorambucil are two biologi-

**Figure 4.** ORTEP drawing of **6A**, at 50 % probability level for thermal displacement ellipsoids, with hydrogen atoms omitted for clarity.

cally active acids, ethacrynic acid is a Glutathione S-Transferase inhibitor (an enzyme involved in the process of detoxification of the cell) [14], while chlorambucil is an alkylating agent inducing death cell by apoptosis [15]. According to the X-ray analysis structures of complexes **2** and **3**, the coordination of ethacrynic acid and chlorambucil do not induce any changes in their structure. They are coordinated to the ruthenium atoms by the carboxylato bridge keeping their active parts free, the methylene group and the two chloro-ethyl arms, respectively. However, complexes **1–4** showed no cytotoxicity on human ovarian cancer cells, due probably to their very low solubility in water.

In conclusion we have synthesized and structurally characterized six new sawhorse-type complexes containing various carboxylato bridging ligands. Additionally, we described a method of synthesis using milder conditions as compared to the classical method.

Acknowledgement

We are grateful to the Fonds National Suisse de la Recherche Scientifique. A generous loan of ruthenium chloride from the Johnson Matthey Technology Centre is also gratefully acknowledged.

References

- [1] G. R. Crooks, B. F. G. Johnson, J. Lewis, I. G. Williams, G. Gamlen, *J. Chem. Soc. (A)* **1969**, 2761.
- [2] H. Schumann, J. Opitz, J. Pickardt, *J. Organomet. Chem.* **1977**, *128*, 253.
- [3] a) M. Bianchi, P. Frediani, U. Matteoli, G. Menchi, F. Piacenti, G. Petrucci, *J. Organomet. Chem.* **1983**, *259*, 207; b) M. Rotem, Y. Shvo, I. Goldberg, U. Shmueli, *Organometallics* **1984**, *3*, 1758; c) G. Süss-Fink, G. Herrmann, P. Morys, J. Ellermann, A. Veit, *J. Organomet. Chem.* **1985**, *284*, 263; d) M. Rotem, I. Goldberg, U. Shmueli, Y. Shvo, *J. Organomet. Chem.* **1986**, *314*, 185; e) P. Frediani, M. Bianchi, F. Piacenti, S. Ianelli, M. Nardelli, *Inorg. Chem.* **1987**, *26*, 1592; f) S. J. Sherlock, M. Cowie, E. Singleton, M. M. de V. Steyn, *Or-*

- ganometallics* **1988**, *7*, 1663; g) G. F. Schmidt, G. Süss-Fink, *J. Organomet. Chem.* **1989**, *362*, 179; h) G. Süss-Fink, J. L. Wolfender, F. Neumann, H. Stoeckli-Evans, *Angew. Chem., Int. Ed. Engl.* **1990**, *29*, 429; i) D. S. Bohle, H. Vahrenkamp, *Inorg. Chem.* **1990**, *29*, 1097; j) P. Frediani, M. Bianchi, A. Salvini, F. Piacenti, S. Ianelli, M. Nardelli, *J. Chem. Soc., Dalton Trans.* **1990**, *1*, 165; k) P. Frediani, M. Bianchi, A. Salvini, F. Piacenti, S. Ianelli, M. Nardelli, *J. Chem. Soc., Dalton Trans.* **1990**, *5*, 1705; l) P. Frediani, M. Bianchi, A. Salvini, F. Piacenti, *J. Chem. Soc., Dalton Trans.* **1990**, *12*, 3663; m) P. Frediani, C. Faggi, S. Papaleo, A. Salvini, M. Bianchi, F. Piacenti, S. Ianelli, M. Nardelli, *J. Organomet. Chem.* **1997**, *536–537*, 123; n) P. Frediani, C. Faggi, A. Salvini, M. Bianchi, F. Piacenti, *Inorg. Chim. Acta* **1998**, *272*, 141; o) P. Frediani, C. Giannelli, A. Salvini, S. Ianelli, *J. Organomet. Chem.* **2003**, *667*, 197; p) M. Auzias, B. Therrien, G. Labat, H. Stoeckli-Evans, G. Süss-Fink, *Inorg. Chim. Acta* **2006**, *359*, 1012; q) M. Auzias, B. Therrien, G. Süss-Fink, *Inorg. Chim. Acta* **2006**, *359*, 3412; r) M. Auzias, B. Therrien, G. Süss-Fink, *Inorg. Chem. Commun.* **2007**, *10*, 1420; s) M. Auzias, G. Süss-Fink, P. Štěpnička, J. Ludvík, *Inorg. Chim. Acta* **2007**, *360*, 2023.
- [4] a) M. Langenbahn, H. Stoeckli-Evans, G. Süss-Fink, *Helv. Chim. Acta* **1991**, *74*, 549; b) M. Auzias, B. Therrien, G. Süss-Fink, P. Štěpnička, J. Ludvík, *J. Organomet. Chem.* **2007**, *692*, 755.
- [5] a) U. Matteoli, M. Bianchi, G. Menchi, P. Frediani, F. Piacenti, *J. Mol. Catal.* **1985**, *29*, 269; b) U. Matteoli, G. Menchi, P. Frediani, M. Bianchi, F. Piacenti, *J. Organomet. Chem.* **1985**, *285*, 281; c) U. Matteoli, G. Menchi, M. Bianchi, F. Piacenti, *J. Organomet. Chem.* **1986**, *299*, 233; d) U. Matteoli, G. Menchi, M. Bianchi, F. Piacenti, *J. Mol. Catal.* **1988**, *44*, 347; e) J. Jenck, P. Kalck, E. Pinelli, M. Siani, A. Thorez, *J. Chem. Soc., Chem. Commun.* **1988**, *21*, 1428; f) J. L. Wolfender, F. Neumann, G. Süss-Fink, *J. Organomet. Chem.* **1990**, *389*, 351; g) U. Matteoli, G. Menchi, M. Bianchi, F. Piacenti, *J. Mol. Catal.* **1991**, *64*, 257; h) A. Salvini, P. Frediani, D. Rovai, M. Bianchi, F. Piacenti, *J. Mol. Catal.* **1994**, *89*, 77; i) U. Matteoli, G. Menchi, M. Bianchi, F. Piacenti, S. Ianelli, M. Nardelli, *J. Organomet. Chem.* **1995**, *498*, 177; j) A. Salvini, P. Frediani, C. Giannelli, L. Rosi, *J. Organomet. Chem.* **2005**, *690*, 371.
- [6] T. Werle, L. Schäffler, G. Maas, *J. Organomet. Chem.* **2005**, *690*, 5562.
- [7] a) R. Deschenaux, B. Donnio, G. Rheinwald, F. Stauffer, G. Süss-Fink, J. Velker, *J. Chem. Soc., Dalton Trans.* **1997**, *22*, 4351; b) S. Frein, M. Auzias, A. Sondenecker, L. Vieille-Petit, B. Guintchin, N. Maringa, G. Süss-Fink, J. Barberá, R. Deschenaux, *Chem. Mater.* **2008**, *20*, 1340.
- [8] M. I. Bruce, C. M. Jensen, N. L. Jones, *Inorganic Syntheses*, Ed. H. D. Kaesz, John & Wiley Sons, Inc. **1989**, *26*, 259.
- [9] G. M. Sheldrick, *Acta Crystallogr.* **1990**, *A46*, 467.
- [10] G. M. Sheldrick, *SHELXL-97*, University of Göttingen, Göttingen, Germany 1999.
- [11] L. J. Farrugia, *J. Appl. Cryst.* **1997**, *30*, 565.
- [12] C. M. Kepert, G. B. Deacon, L. Spiccia, G. D. Fallon, B. W. Skelton, A. H. White, *J. Chem. Soc., Dalton Trans.* **2000**, 2867.
- [13] F. Schmitt, M. Auzias, P. Štěpnička, Y. Sei, K. Yamaguchi, G. Süss-Fink, B. Therrien, L. Juillerat-Jeanneret, *manuscript in preparation*; cf. M. Auzias, Ph. D. thesis, Université de Neuchâtel, **2008**.
- [14] W. H. Ang, A. De Luca, C. Chapuis-Bernasconi, L. Juillerat-Jeanneret, M. Lo Bello, P. J. Dyson, *Chem. Med. Chem.* **2007**, *2*, 1799.
- [15] L. Panasci, J. P. Paiement, G. Christodoulouopoulos, A. Belenkov, A. Malapetsa, R. Aloyz, *Clin. Cancer Res.* **2001**, *7*, 45.